RxDoctor Payments Data

Alexis Mitchell

Nurse Practitioner · Atlanta, GANPI 1356851406

Payments from drug & device makers

$493in general payments, 2019–2025

Across 20 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$186
  • Janssen Products, LP$70
  • Johnson & Johnson$62
  • Janssen Scientific Affairs, LLC$51
  • BD$41
  • Hologic Sales And Service, LLC$39
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$42386%
  • Education$7014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$493 in reported general payments places this provider in the 65th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$6,424
Medicare patients
48
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala59$227,087
TriumeqAbacavir/Dolutegravir/Lamivudi28$104,827
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$102,632
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$91,566
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf19$88,178
DescovyEmtricitabine/Tenofov Alafenam20$40,913
TivicayDolutegravir Sodium18$37,332
PrezcobixDarunavir/Cobicistat12$28,138
Atorvastatin Calcium17$37
Levothyroxine Sodium12$35
Amlodipine Besylate31$32
Sertraline Hcl11$32
Lisinopril26$23
Trazodone Hcl11$11
Hydrochlorothiazide14$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay$186$142,15946 claims
Janssen Products, LPSymtuza$70$88,17819 claims
Johnson & JohnsonPrezcobix$62$28,13812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →